Serum alpha-CGRP levels are increased in COVID-19 patients with headache indicating an activation of the trigeminal system
暂无分享,去创建一个
M. Toriello | J. Pascual | J. Olmos | V. González‐Quintanilla | S. Pérez-Pereda | J. Madera | G. Gárate | M. Pascual
[1] M. Toriello,et al. Serum Calcitonin Gene-Related Peptide α and β Levels are Increased in COVID-19 Inpatients , 2022, Archives of Medical Research.
[2] A. Gursoy,et al. Is Persistent Post-COVID Headache Associated With Protein-Protein Interactions Between Antibodies Against Viral Spike Protein and CGRP Receptor?: A Case Report , 2022, Frontiers in Pain Research.
[3] J. Crespo,et al. Increase in Serum Calcitonin Gene-Related Peptide β (CGRPβ) Levels in COVID-19 Patients with Diarrhea: An Underlying Mechanism? , 2022, Digestive Diseases and Sciences.
[4] D. García‐Azorín,et al. Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients , 2022, Cephalalgia : an international journal of headache.
[5] P. Pozo‐Rosich,et al. Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks , 2021, Cephalalgia : an international journal of headache.
[6] K. Messlinger,et al. Activation of the trigeminal system as a likely target of SARS-CoV-2 may contribute to anosmia in COVID-19 , 2021, Cephalalgia : an international journal of headache.
[7] Á. G. Guerrero Peral,et al. Frequency and phenotype of headache in covid-19: a study of 2194 patients , 2021, Scientific Reports.
[8] H. Bolay,et al. HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism , 2021, The Journal of Headache and Pain.
[9] G. Coppola,et al. How does the brain change in chronic migraine? Developing disease biomarkers , 2020, Cephalalgia : an international journal of headache.
[10] D. Kaya,et al. Reader response: Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry , 2020 .
[11] J. Álvarez-Sabín,et al. Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution , 2020, Cephalalgia : an international journal of headache.
[12] P. Rocha-Filho,et al. Headache associated with COVID-19: Frequency, characteristics and association with anosmia and ageusia , 2020, Cephalalgia : an international journal of headache.
[13] M. Fowkes,et al. Circulating levels of calcitonin gene-related peptide (CGRP) are lower in COVID-19 patients , 2020, medRxiv.
[14] H. Bolay,et al. COVID‐19 is a Real Headache! , 2020, Headache.
[15] Carrie E. Robertson,et al. Could CGRP Antagonists Be Helpful in the Fight Against COVID‐19? , 2020, Headache.
[16] T. Sobrino,et al. CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study , 2018, Headache.
[17] Thomas Hankemeier,et al. Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis , 2017, Cephalalgia : an international journal of headache.
[18] P. Martínez-Camblor,et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine , 2013, Neurology.
[19] P. Goadsby,et al. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache , 1990, Annals of neurology.